Progress in the clinical trial for bacterial vaginosis

Now, 57 patients, patients have been enrolled in the NEFERTITI clinical trial. Thanks to persistent and inventive investigators, in Sweden and in England, the study progresses at a steady pace. The NEFERTITI study examines the clinical effect of Gedea's treatment of pHyph in bacterial vaginosis, both as a treatment and prevention of recurrent infections. 150 patients will be included and 25% of them will receive placebo treatment during the first 7 days of the study. After 7 days, patients who have been cured will be re-randomized to a follow-up period of 18 weeks where 50% will receive placebo and 50% will receive pHyph, 1 tablet per week.

Martin Stjernquist is a gynecologist at a clinic in Malmö and investigator in the study:Martin Stjernquist
- Many women have problems with bacterial vaginosis, which often involves foul-smelling discharge. It is a major problem for those affected and the infection often reoccurs. This study is important because it can lead to new treatment options that reduce the risk of recurring symptoms.

Sten Kornfält, clinical project manager at Gedea, says that the investigators in the NEFERTITI study show great commitment:
- We see that the investigators tacare very much for their patients and want to contribute to developing a new treatment of vaginal infections.

The clinic in Malmö has so far recruited the most patients for the study and Martin Stjernquist believes that the clinic's teamwork is a success factor:
- The study nurse calls the patients before the visit and asks some questions to ensura that the study is right for the patient. 

Women who are interested in participating in the study can register their interest via this link